Anatomic characteristics and clinical implications of angiographic coronary thrombus: insights from a patient-level pooled analysis of SYNTAX, RESOLUTE, and LEADERS Trials. by Campos, Carlos M et al.
1Coronary thrombus has been associated with acute coro-nary syndromes and disease progression. The rupture 
of thin cap fibro-atheromas allows the blood to come in con-
tact with the highly thrombogenic contents of the plaque (eg, 
necrotic core/collagen) favoring the occurrence of most of 
acute coronary syndromes.1,2 In addition, invasive imaging 
studies have shown that coronary thrombosis can also be pres-
ent in stable coronary artery disease (CAD) and has been asso-
ciated with plaque progression.3,4
Thrombus-containing lesions (TCLs) seems to be associ-
ated with an increased risk of distal embolization and no or 
poor distal flow and low myocardial blush grades after per-
cutaneous coronary intervention.5,6 However, the prognostic 
relevance of coronary thrombus as assessed by angiography 
is still unclear, and the results presented in the literature are 
disputed.7–9
The aim of the present study is to examine the angiographic 
anatomic characteristics of TCL and their correlations with 
clinical events (all-cause death, myocardial infarction [MI], 
and all revascularizations) in the largest-ever pooled all-comer 
population enrolled in contemporary percutaneous coronary 
intervention trials.
Background—The distribution of thrombus-containing lesions (TCLs) in an all-comer population admitted with a 
heterogeneous clinical presentation (stable, ustable angina, or an acute coronary syndrome) and treated with percutaneous 
coronary intervention is yet unclear, and the long-term prognostic implications are still disputed. This study sought 
to assess the distribution and prognostic implications of coronary thrombus, detected by coronary angiography, in a 
population recruited in all-comer percutaneous coronary intervention trials.
Methods and Results—Patient-level data from 3 contemporary coronary stent trials were pooled by an independent academic 
research organization (Cardialysis, Rotterdam, the Netherlands). Clinical outcomes in terms of major adverse cardiac 
events (major adverse cardiac events, a composite of death, myocardial infarction, and repeat revascularization), death, 
myocardial infarction, and repeated revascularization were compared between patients with and without angiographic 
TCL. Preprocedural TCL was present in 257 patients (5.8%) and absent in 4193 (94.2%) patients. At 3-year follow-up, 
there was no difference for major adverse cardiac events (25.3 versus 25.4%; P=0.683); all-cause death (7.4 versus 6.8%; 
P=0.683); myocardial infarction (5.8 versus 6.0%; P=0.962), and any revascularizations (17.5 versus 17.7%; P=0.822) 
between patients with and without TCL. The comparison of outcomes in groups weighing the jeopardized myocardial by 
TCL also did not show a significant difference. TCL were seen more often in the first 2 segments of the right (43.6%) and 
left anterior descending (36.8%) coronary arteries. The association of TCL and bifurcation lesions was present in 40.1% 
of the prespecified segments.
Conclusions—TCL involved mainly the proximal coronary segments and did not have any effect on clinical outcomes. 
A more detailed thrombus burden quantification is required to investigate its prognostic implications.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00114972, NCT01443104, 
NCT00617084.  (Circ Cardiovasc Interv. 2015;8:e002279. DOI: 10.1161/CIRCINTERVENTIONS.114.002279.)
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Methods
Patient Population
We analyzed patient-level data from 3 all-comer coronary drug-
eluting stent trials: LEADERS (Limus Eluted From a Durable Versus 
Erodable Stent Coating) trial, RESOLUTE (Resolute All Comers) 
trial, and SYNTAX (Synergy Between Percutaneous Coronary 
Intervention With Taxus and Cardiac Surgery). Detailed individual 
study design and trial results are available elsewhere.10–12 In brief, 
all studies included patients with obstructive CAD that was amend-
able to coronary stent implantation (Table I in the Data Supplement). 
These trials had an all-comers design, but in the SYNTAX trial, the 
enrolled patients must had complex (3-vessel or left main) CAD to be 
enrolled. All studies complied with the Declaration of Helsinki and 
were approved by the ethical review board in each institution. All pa-
tients provided written, informed consent for participation in the indi-
vidual study. The angiographic images were reviwed by independent 
core laboratory analysts (Cardialysis, Rotterdam, The Netherlands) 
who identify the presence or absence of thrombus. Aiming to evaluate 
the clinical characteristics and prognosis, the patients were divided 
into 2 groups according to the presence or absence of at least one TCL 
as assessed by coronary angiography.
Clinical Outcomes
Major adverse cardiac events (MACE) were defined as a composite 
of all-cause death, MI, and any repeat revascularization. There was a 
wide variation in the definition of MI among studies. This is because 
of each study inclusion criteria, variations in study design, and the 
different periods during which studies were performed. Because all 
clinical events from each individual trial were adjudicated by inde-
pendent clinical event committees, no attempt was made to readjudi-
cate MI events in the different trials to compensate for the differences 
in individual definition of MI. Therefore, all MIs reported in the cur-
rent study are as per individual study protocol definitions.
WhAT IS KNOWN
•	The effect of coronary thrombus on prognosis is dis-
puted, particularly in the era of sophisticated coro-
nary intervention.
WhAT ThE STUDY ADDS
•	 In a population with a broad spectrum of coronary 
disease, the presence of intracoronary thrombus was 
not associated with an increased incidence of ad-
verse outcomes.
•	Thombi were most commonly located in proxi-
mal coronary locations and at the site of coronary 
bifurcations.
Table 1. Segment Weighing Factor
Segment No. Right Dominance Left Dominance
1 1 0
2 1 0
3 1 0
4 1 na
16 0.5 na
16a 0.5 na
16b 0.5 na
16c 0.5 na
5 5 6
6 3.5 3.5
7 2.5 2.5
8 1 1
9 1 1
9a 1 1
10 0.5 0.5
10a 0.5 0.5
11 1.5 2.5
12 1 1
12a 1 1
12b 1 1
13 0.5 1.5
14 0.5 1
14a 0.5 1
14b 0.5 1
15 na 1
Table 2. Baseline Clinical Characteristics
Pts Without 
Thrombus 
Containing  
Lesions 
N=4193
Pts With  
Thrombus 
Containing 
Lesions 
N=257 P Values
Age 64.6±107 62.7±10.7 0.006
Male, % 3127 (74.6) 208 (80.9) 0.022
Diabetes mellitus, % 1032 (24.6) 50 (19.5) 0.061
Body mass index, kg/m2 27.7±4.5 27.8±4.5 0.831
Hypertension, % 3061 (73.0) 150 (58.4) <0.001
Hyperlipidemia, % 2842 (67.8) 136 (52.9) <0.001
Current smoker, % 1279 (30.5) 132 (51.4) <0.001
Peripheral vascular 
disease, %
317 (7.6) 16 (6.2) 0.446
Family history of 
premature CAD, %
1443 (27.3) 87 (33.9) 0.518
History of stroke/ 
TIA, %
222 (5.3) 13 (5.1) 0.849
Creatinine >200 
μmol/L
1.3 0.4 0.530
Creatinine 
clearance, mL/min
90.6±37.4 98.7±33.9 0.001
Previous 
myocardial 
infarction, %
1225 (29.2) 55 (21.4) 0.006
Previous PCI, % 1027 (24.5) 32 (12.5) <0.001
Presentation <0.001
  NSTEMI, % 558 (13.3) 62 (24.1)
  Stable CAD, % 2131 (50.8) 50 (14.0)
  STEMI, % 539 (12.9) 112 (43.6)
  Unstable angina, % 965 (23.0) 33 (12.8)
LVEF, % 56.8±11.9 54.7±11.9 0.052
CAD indicates coronary artery disease; LVEF, left ventricular ejection 
fraction; MI, myocardial infarction; NSTEMI, non–ST-segment–elevation 
myocardial infarction; PCI, percutaneous coronary intervention; Pts, 
patients; STEMI,  ST-segment–elevation myocardial infarction; and TIA, 
transient ischemic attack.
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Angiographic Assessment
The angiographic assessment was performed by an independent 
corelab (Cardialysis, Rotterdam, The Netherlands) based on the 
SYNTAX score concept. The SYNTAX score for each patient was 
calculated by scoring all coronary lesions with a diameter stenosis 
≥50%, in vessels ≥1.5 mm, using the SYNTAX score algorithm, 
which is described in full elsewhere.13 All angiographic variables 
were recorded prospectively by a team of 2 core laboratory analysts.
A bifurcation was classified by a division of a main, parent, branch 
into 2 daughter branches of at least 1.5 mm diameter according to 
the Medina classification.14 The smaller of the 2 daughter branches 
was designated as the side branch. After the SYNTAX score recom-
mendations, bifurcations were only scored for the following seg-
ment junctions: 5/6/11, 6/7/9, 7/8/10, 11/13/12a, 13/14/14a, 3/4/16, 
and 13/14/15. Coronary thrombus was defined according to the 
Academic Research Consortium definition as spheric, ovoid, or ir-
regular intraluminal filling defect or lucency surrounded on 3 sides 
by contrast medium seen just distal or within the coronary stenosis in 
multiple projections or a visible embolization of intraluminal mate-
rial downstream.15 To further evaluate the prognostic effect of throm-
bus, the summation of segment weighing factors (Table 1) used in the 
SYNTAX score was used if TCLs were present.
Data Analysis
All patients with a calculated SYNTAX score were included in the 
analysis. Discrete data were summarized as percent (frequencies) 
and were compared using the chi-squared test. Continuous data were 
expressed as mean±SD and were compared using Student’s t test or 
Wilcoxon rank-sum test based on their distributions. Survival curves 
were constructed for time-to-event variables using Kaplan–Meier 
estimates and compared by the log-rank test. Comparison of events 
rates between groups were adjusted for confounding factors in a Cox-
regression model. All variables were stratified according to presence 
of at least one TCL using a Cox-regression model. The differences 
were regarded significant when P<0.05 (2-tailed). The Breslow-
Day chi-squared test was calculated to test the statistical evidence 
of heterogeneity across the studies (P<0.1). The chi-squared test and 
I2 statistic were calculated to test the statistical evidence of hetero-
geneity across the studies16 (Table II and Figures I–V in the Data 
Supplement). SPSS version 21.0 (SPSS Inc, Chicago, IL) was used 
for all other statistical analyses.
Results
Baseline Characteristics
Table 2 depicts patients’ baseline demographics. Prepro-
cedural thrombus was present in 257 patients (5.8%) and 
absent in 4193 (94.2%). Patients with at least one TCL were 
younger (62.7±10.7 versus 64.6±10.7; P=0.006), more fre-
quently male (80.9% versus 74.6%; P=0.022) and current 
smokers (51.4% versus 30.5%; P<0.001), less likely to have 
Table 3. Baseline Angiographic Characteristics
Pts Without Thrombus 
Containing Lesions, N=4193
Pts With Thrombus 
Containing Lesions, N=257 P Values
Baseline SYNTAX score±SD 17.7±11.6 18.6±10.7 0.239
Number of total occlusions/patient±SD 0.27±0.49 0.37±0.56 0.010
Number of aorto-ostial lesions/patient±SD 0.06±0.25 0.07±0.27 0.714
Number of lesions with severe tortuosity/ 
patient±SD
0.81±1.09 0.73±1.07 0.265
Number of lesions with length >20 mm/ 
patient±SD
0.51±0.76 0.51±0.65 0.884
Number of lesions with heavy calcification/ 
patient±SD
0.40±0.87 0.35±0.82 0.367
Number segments with diffuse disease/ 
patient±SD
0.04±0.19 0.04±0.18 0.877
Lesions in left main/patient 0.10±0.31 0.07±0.26 0.086
Lesions in LAD proximal/patient 0.33±0.50 0.34±0.50 0.820
Lesions in LAD mid/patient 0.58±0.58 0.54±0.58 0.243
Lesions in LAD apical/patient 0.15±0.38 0.13±0.36 0.275
Lesions in first diagonal/patient 0.25±0.45 0.28±0.48 0.247
Lesions in second diagonal/patient 0.01±0.11 0.02±0.12 0.722
Lesions in proximal circumflex/patient 0.19±0.40 0.17±0.37 0.481
Lesions in distal circumflex/patient 0.35±0.52 0.30±0.49 0.116
Lesions in intermediate/patient 0.08±0.27 0.09±0.31 0.416
Lesions in first obtuse marginal/patient 0.13±0.34 0.13±0.34 0.686
Lesions in second obtuse marginal/patient 0.12±0.34 0.09±0.29 0.107
Lesions in RCA proximal/patient 0.27±0.45 0.33±0.47 0.045
Lesions in RCA mid/patient 0.34±0.49 0.34±0.48 0.983
Lesions in RCA distal/patient 0.25±0.46 0.27±0.48 0.447
Lesions in posterolateral/patient 0.07±0.25 0.05±0.23 0.21
Lesions in posterior descending /patient 0.01±0.09 0.00±0.00 0.17
LAD indicates left anterior descending coronary artery; Pts, patients; RCA, right coronary artery; and SYNTAX, Synergy Between 
Percutaneous Coronary Intervention With Taxus and Cardiac Surgery.
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hypertension (58.4% versus 73.0%; P<0.001), and hyperlip-
idemia (52.9 versus 67.8%; P<0.001). The left ventricular 
ejection fraction tended to be higher in patients without TCL 
(56.8±11.9 versus 54.7±11.9; P=0.052). Presence of throm-
bus at baseline was more frequently related with an acute pre-
sentation (P<0.001).
Angiographic Characteristics
Patients with and without TCL had similar angiographic 
characteristics (Table 3). There were differences for higher 
prevalence of total occlusions (0.37±0.56 versus 0.27±0.49 
total oclusions/patient; P=0.010) and more frequent involve-
ment of the proximal right coronary artery (0.33±0.47 versus 
0.27±0.45 lesions/patient; P=0.045) in the thrombus group.
Clinical Outcomes
There was no difference between the groups (Table 4 and 
Figure 1) for any of the studied outcomes ≤3-year follow-up. 
MACE occurred in 1067 patients (25.4%) in the group with-
out thrombus at baseline and 65 (25.3%) in the group with 
thrombus (P=0.874). Consistently, all-cause death (P=0.683), 
MI (P=0.962), and any revascularization (P=0.822) was not 
significantly different in the 2 groups.
Subgroup Analysis
In the stratified analysis, the occurrence of MACE was 
homogenously distributed across the clinical and angio-
graphic covariates, with the only exception of clinical presen-
tation (Figure 2). There was a significant interaction between 
the patients presenting with acute coronary syndrome (hazard 
ratio 0.881, confidence interval 0.65–1.19) and stable CAD 
(hazard ratio 1.637, 95% confidence interval 1.04–2.59) with 
respect to the presence of thrombus at baseline (P=0.028).
A more detailed analysis of the subgroup with stable 
CAD can be found in Table III in the Data Supplement. The 
thrombus at baseline was related to a higher rate of MACE 
(38% versus 26%, P=0.03) mainly because of an increased 
rate of repeated revascularization (30% versus 18%, P=0.01). 
However, after adjustment for confounders (ie, age, creatinine 
Table 4. Kaplan–Meier Events Rate Comparison Between 
Groups
Pts Without 
Thrombus 
Containing Lesions, 
N=4193
Pts With  
Thrombus 
Containing 
Lesions, N=257 P Values
30 days, n (%)
  MACE 254 (6.1) 17 (6.6) 0.714
  All-cause death 47 (1.1) 3 (1.2) 0.937
  All MI 163 (3.9) 9 (3.5) 0.754
  All revascularization 114 (2.7) 11 (4.3) 0.131
1-year
  MACE 669 (16.0) 48 (18.7) 0.229
  All-cause death 127 (3.0) 10 (3.9) 0.423
  All MI 196 (4.7) 11 (4.3) 0.778
  All revascularization 480 (11.5) 35 (13.7) 0.217
3-year
  MACE 1067 (25.4) 65 (25.3) 0.874
  All-cause death 287 (6.8) 19 (7.4) 0.683
  All MI 250 (6.0) 15 (5.8) 0.962
  All revascularization 742 (17.7) 45 (17.5) 0.822
MACE indicates major adverse cardiac events (composite of all-cause death, 
myocardial infarction, and all revascularization); and MI, myocardial infarction.
Figure 1. Kaplan–Meier cumulative curves for MACE (A; composite of all-cause death, myocardial infarction, and all revascularizations), all-cause 
death (B), myocardial infarction (MI; C), and all revascularizations (D). MACE indicates major adverse cardiac events; and MI, myocardial infarction.
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clearance, previous MI, LVEF, and number of total occlusions/
patient), this effect was no longer present (Figures VIA–VID 
and VIIA–VIID in the Data Supplement).
Anatomic Characteristics of Thrombus Containing 
Lesions
In the subgroup of patients with TCL (n=257), 261 lesions had 
angiographic thrombus. As shown in Figure 3, the presence 
of TCL occurred preferentially in proximal segments. More 
specifically, 43.6% of these complex lesions were seen in the 
first 2 segments of the right coronary artery and 36.8% in the 
first 2 segments of the left anterior descending coronary artery.
As demonstrated in Figure 4, TCLs were seen often in cor-
onary bifurcations. The association of thrombus-containing 
and bifurcation lesions was present in 40.1% of the aforemen-
tioned prespecified segments. In the left anterior descending 
coronary artery, there was appreciable coexistence of throm-
bus and bifurcation lesions (45.9% of the lesions). On the other 
hand, the combination thrombus–bifurcation was not frequent 
in the distal right coronary artery (8.6% of the lesions).
Figure 3. Distribution of angiographic thrombus containing lesions.
Figure 2. Stratified analysis for MACE (composite of all-cause death, all myocardial infarction, and all revascularizations according to the pres-
ence or absence of thrombus containing lesions. ACS indicates acute coronary syndromes; CAD, coronary artery disease; CI, confidence 
interval; CrCl, creatinine clearance; DM, diabetes mellitus; HR, hazard ratio; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac 
events; SS, anatomic SYNTAX score; and SYNTAX, Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery.
 by guest on January 29, 2016http://circinterventions.ahajournals.org/Downloaded from 
6  Campos et al  Implications of Angiographic Coronary Thrombus  
Clinical Outcomes According to Myocardium at Risk
We divided the subgroup of patients with TCL into tertiles of 
the sum of segment weighing factors (Table 1). As shown in 
Figure 5, the weighting for myocardium at risk did not pro-
duce significant difference in outcomes (MACE, all-cause 
death, MI or all revascularizations) for patients with TCL.
Figure 5. Kaplan–Meier cumulative curves for MACE (A; composite of all-cause death, myocardial infarction and all revascularizations), 
all-cause death (B), myocardial infarction (MI; C), and all revascularizations (D) according to tertiles of the sum of segment weighing fac-
tors in patients with thrombus-containing lesions.
Figure 4. Per-segment association of thrombus and bifurcation lesions according to Medina14 classification. Dg indicates diagonal 
branch; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; LM, left main coronary artery; Mg, marginal; 
PD, Posterior descending branch; Pl, posterolateral branch; and RCA, right coronary artery.
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Discussion
The findings of our study can be summarized as follows: (1) TCL 
were seen more often in the proximal segments; (2) there was a 
considerable coexistence of bifurcation and TCLs; (3) the pres-
ence of thrombus at baseline was not related to any additional risk 
of MACE, even after weighing for myocardium at risk.
Anatomy of Angiographic Coronary Thrombus
Coronary thrombus is mostly formed after rupture of athero-
sclerotic lesions containing a large necrotic core and a thin 
fibrous cap.1,2 In the present study, we found that thrombus 
was angiographically detected in the proximal coronary seg-
ments and mainly in the right and left anterior descending 
coronary arteries. Our results are similar to those reported by 
Wang et al who analyzed coronary angiograms from 208 con-
secutive patients presented with ST-elevation MI.17 However, 
in their methodology, they were evaluating the site of coronary 
occlusion. Although they used a slightly different coronary 
segmentation (BARI classification), they also have found that 
the 2 most proximal segments of right coronary artery and 
left anterior descending coronary artery were also responsible 
for the absolute majority (65.4%) of acute coronary occlu-
sion.17 In the present analysis, a 25-fold larger population was 
studied and included a population with a broader spectrum of 
the disease (also stable CAD and NSTEMI) in which the ves-
sel occlusion was not mandatory for diagnosis of thrombus. 
Importantly, all angiographic assessments were performed by 
an experienced independent core laboratory, which has proven 
to have a higher consistency and better prognostic discrimina-
tion than investigator-reported angiographic findings.18
Interestingly, distribution of thin cap fibroatheroma, 
as assessed by virtual histology intravascular ultrasound 
(VH-IVUS) and optical coherence tomography, resembles the 
distribution of thrombus found in the present study; this may 
indicate that thin cap fibroatheromas are the underlying sub-
strate of coronary thrombus found in this study19,20 (Table 5). 
These invasive imaging findings are also in line with previous 
anatomopathological studies.2,4,21
It has to be highlighted, however, that angiography, because 
of its limited resolution, is far from being the gold stan-
dard tool for coronary thrombus diagnosis. For instance, in 
the present analysis, there was a low percentage (9.2%) of 
patients with acute coronary syndromes that were classified 
as having TCL. Similarly, Goto et al detected angiographic 
thrombus in only 14.6% of patients in a population of exclu-
sively acute coronary syndromes.7 Importantly, although Goto 
et al defined thrombus as “an intraluminal filling defect or an 
area of contrast staining noted within the target stenosis,”7 we 
used the definition recommended by the Academic Research 
Consortium.15
Another interesting aspect of our findings is the relatively 
frequent association between thrombus and bifurcation. In 
the LAD, a bifurcation lesion was present in almost half of 
the TCL. The most plausible explanations for this associa-
tion are the following: (1) the most frequent location of thin 
cap fibroatheromas is in bifurcation22 and (2) the endothelial 
shear stress in coronary bifurcations has a particular distri-
bution. In relatively straight segments, the endothelial shear 
stress is pulsatile and unidirectional.23 Conversely, in coronary 
bifurcations, disturbed laminar flow occurs, and pulsatile flow 
generates low or oscillatory endothelial shear stress.23 The role 
of endothelial shear stress in more advanced atherosclerosis 
was demonstrated 45 years ago24 and have been reproduced 
in autopsy-based coronary models, human in vivo studies in 
arterial models derived from intravascular ultrasound or mag-
netic resonance, and in vivo animal experiments.23,25
Thrombus and Clinical Events
In the present study, the presence of thrombus did not have 
any effect on clinical events, even when it was adjusted for 
the amount of myocardial at risk. Corroborating our findings, 
Singh et al have shown that the introduction of the coronary 
stents and the use of more contemporary antiplatelet therapy 
made the presence of thrombus irrelevant for long-term death 
and MI.8 On the other hand, Sianos et al have demonstrated 
that large thrombus burden is an independent predictor of 
Table 5. Distribution of Complex Coronary Lesions
% in Proximal 
Segment
% in Mid 
Segment % Total
Wang et al17
  Observation: Site of coronary 
occlusion distribution, %
   RCA 12.5 14.4 26.9
   LAD 14.5 24.0 38.5
   LCX 8.6 4.3 13.0
   LM ... ... 0.5
Present study
  Observation: Thrombus 
containing lesions 
distribution, %
   RCA 21.8 21.8 43.7
   LAD 18.0 18.8 36.8
   LCX 7.7 5.0 12.6
   LM ... ... 2.7
PROSPECT substudy19
  Observation: VH-TCFA– 
containing lesion distribution, %
   RCA 17.1 15.1 32.2
   LAD 24.2 10.8 35
   LCX 15.2 11.8 27
   LM ... ... n.a.
Tian et al20
  Observation: OCT- 
TCFA–containing lesion 
distribution, %
   RCA n.a. n.a. 45.0
   LAD n.a. n.a. 35.9
   LCX n.a. n.a. 19.1
   LM ... ... n.a.
LAD indicates left anterior descending coronary artery; LCX, left circumflex 
coronary artery; LM, left main coronary artery; OCT, optical coherence 
tomography; RCA, right coronary artery; TCFA, thin cap fibroatheroma; and VH, 
virtual histology intravascular ultrasound.
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major adverse events (defined as death, repeat MI infarct-
related artery infarct-related artery) in patients treated with 
drug-eluting stents for STEMI.9 Additionally, large throm-
bus burden has been related to larger myocardial damage as 
detected by contrast-enhanced cardiac magnetic resonance.26 
The aforementioned findings suggest that, for clinical prog-
nostic discrimination, the angiographic thrombus assessment 
should be no longer classified as a binary variable but as a 
more detailed thrombotic burden quantification.
Limitations
The present study has all inherent limitations of a post hoc 
analysis. In addition, the number of stable patients with TCL 
was limited and may have hindered an accurate risk estima-
tion in this subset. The classification of bifurcation lesions 
was restricted to those defined by the SYNTAX score, and 
we could not stablish whether TCL could be associated with 
smaller side branches. However, the use of the SYNTAX 
score concepts have demonstrated consistent prognostic effect 
for percutaneous coronary intervention–treated patients.12,27–29 
Information on thrombus aspiration was not available in this 
study. Nevertheless, the recent Thrombus Aspiration in ST-
Elevation MI in Scandinavia (TASTE) trial showed that rou-
tine thrombus aspiration exclusively in a context of primary 
percutaneous coronary intervention did not reduce the rate 
of death from any cause or the composite of death from any 
cause, rehospitalization for MI, or stent thrombosis at 1 year.30 
Also, the Trial of Routine Aspiration Thrombectomy With 
Percutaneous Coronary Intervention (PCI) Versus PCI Alone 
in Patients With ST-Segment–Elevation Myocardial Infarc-
tion (STEMI) Undergoing Primary PCI (TOTAL) randomly 
assigned 10 732 patients with STEMI undergoing primary PCI 
to routine manual thrombectomy versus PCI alone. Manual 
thrombectomy did not reduce the risk of cardiovascular death, 
recurrent myocardial infarction, cardiogenic shock, or New 
York Heart Association (NYHA) class IV heart failure within 
180 days but was associated with an increased rate of stroke 
within 30 days.31
Conclusions
In this patient-level pooled analysis of 3 contemporary, all-
comers stent trials, coronary TCL involved mainly the proximal 
coronary segments and frequently bifurcations. Angiographic 
thrombus did not have any effect on 3-year MACE, demon-
strating that a more detailed thrombus burden quantification is 
required to investigate its prognostic implications.
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None.
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Supplemental Methods:  
 
Discrete data were summarized as percent (frequencies) and were compared using the chi-
squared test.  Continuous data were expressed as mean±SD and were compared using Student’s t-
test or Wilcoxon rank-sum test based on their distributions. Survival curves were constructed for time-
to-event variables using Kaplan-Meier estimates and compared by the log-rank test. Comparison of 
events rates between groups were adjusted for confounding factors in a Cox-regression model.  All 
variables were stratified according to presence of at least one TCL using a Cox-regression model. 
The differences were regarded significant when p<0.05 (two-tailed). The Breslow-Day chi-squared 
test was calculated to test the statistical evidence of heterogeneity across the studies (p<0.1). The 
chi-squared test and I2 statistic was calculated to test the statistical evidence of heterogeneity across 
the studies 1  (Supplementary Table 2, supplementary Figures 1-5). SPSS version 21.0 (SPSS Inc., 
Chicago, Illinois) was used for all other statistical analyses.
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Supplemental Tables 
Table 1. Summary of the trials included in the present analysis 
 LEADERS2 RESOLUTE3 SYNTAX4 
Enrolment Period 11/2006-05/2007 04/2008-10/2008 03/2005-04/2007 
Study Design RCT RCT RCT 
Number of Patients  1707 2292 1101 
Number of Patients 
with SYNTAX score 
Total (acute†) 
1352 
(535) 
2026 
(736) 
1072 
(0) 
Stents Used SES , BES EES, ZES PES 
Inclusion criteria 
 
Patients aged ≥18 years old AND 
Presentation: Stable angina, ACS, STEMI AND 
≥1 lesion ≥50% DS in vessel with RVD 2.25-4.00mm* 
No restriction on total number of treated lesions, treated vessels, 
lesion length or number of stents implanted. 
 
Presentation: stable angina, unstable angina 
or silent ischaemia, AND  
>50% DS in three major epicardial coronary 
arteries and/or LMS 
No restriction on the total implanted stent 
length.  
 
Exclusion criteria 
 
Inability to take dual anti-platelet therapy 
Allergy to study medicines 
Terminal illness <6 months life expectancy 
Pregnancy 
Participation in another trial 
 
Previous PCI or CABG 
Acute MI 
Need for concomitant cardiac surgery 
Study Procedure 
Stenting procedure at operator’s discretion;  
Direct stenting was allowed 
Aim for complete revascularisation 
DAPT  
Aspirin† 100mg  ≥75mg ≥70mg  
Clopidogrel 
(duration) 
75mg  
(12 months) 
75 mg  
(12 months) 
75 mg  
( ≥ 6 months) 
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 LEADERS2 RESOLUTE3 SYNTAX4 
 
Giulio G Stefanini, Bindu 
Kalesan,  Patrick W Serruys, 
Dik Heg, Pawel Buszman, Axel 
Linke,  Thomas Ischinger, 
Volker Klauss, Franz Eberli, 
William Wijns, Marie-Claude 
Morice,  Carlo Di Mario, 
Roberto Corti, Diethmar Antoni, 
Hae Y Sohn, Pedro Eerdmans, 
Gerrit-Anne van Es,  Bernhard 
Meier, Stephan Windecker 
Patrick W. Serruys, Sigmund 
Silber, Scot Garg, Robert Jan 
van Geuns, Gert Richardt,  
Pawel E. Buszman, Henning 
Kelbæk, Adrianus Johannes 
van Boven, Sjoerd H. Hofma, 
Axel Linke, Volker Klauss, 
William Wijns, Carlos Macaya, 
Philippe Garot, Carlo DiMario, 
Ganesh Manoharan, Ran 
Kornowski, Thomas Ischinger, 
Antonio Bartorelli, Jacintha 
Ronden, Marco Bressers, 
Pierre Gobbens. Manuela 
Negoita, Frank van Leeuwen 
and Stephan Windecker 
Patrick W. Serruys, Marie-Claude Morice, A. 
Pieter Kappetein, Antonio Colombo, David R. 
Holmes, Michael J. Mack, Elisabeth Ståhle, 
Ted E. Feldman, Marcel van den Brand,  Eric 
J. Bass,  Nic Van Dyck,  Katrin Leadley,  Keith 
D. Dawkins and Friedrich W. Mohr 
 
 *2.25-3.50mm in LEADERS 
 †Acute- ST-elevation and Non-ST elevation myocardial infarction 
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Table 2. Assessment of heterogeneity among the trials: 
 
Endpoint Chi-square P value I2 
All-cause death 0.13 51% 
All revascularizations 0.20 38% 
Myocardial Infarction 0.69 0% 
MACE (composite by death, 
myocardial infarction and all 
revascularizations) 
0.02 74% 
  
There was a significant heterogeneity for MACE (Supplemental Figure 1) but interestingly was not 
caused by the SYNTAX trial (Supplemental Figures 2-4). The Supplemental Figure 5 shows the 
combined OR using Bayesian random effects in which thrombus containing lesion (TCL) did not have 
impact on long-term occurrence of MACE.  
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Table 3. Baseline clinical and angiographic characteristics according the presence/absence of 
thrombus in patients with stable coronary artery disease 
 
 
 
 
 
 
 
 
Without 
thrombus 
N=2131 
With 
thrombus 
N=50 
P 
Age 63.6±11.2 61.8±11.9 0.031 
Male,% 1610 (75.6) 39 (78.0) 0.868 
Diabetes Mellitus,% 595 (27.9) 18 (36.0) 0.206 
Body mass index, kg/m2 27.7±4.5 27.5±4.6 0.527 
Hypertension,% 1613 (75.7) 40 (80.0) 0.616 
Hyperlipidemia,% 1578 (74.0) 35 (70.0) 0.517 
Current smoker,% 524 (24.6) 13 (26.0) 0.794 
Peripheral vascular disease,% 190 (8.9) 4 (8.0) 0.767 
Family history of premature CAD,% 1394 (65.4) 34 (68.0) 0.756 
History of Stroke/TIA,% 128 (6.0) 5 (10.0) 0.209 
Creatinine>200 micromol/L 32 (1.5) 0 (0.0) 1.000 
Creatinine clearance; ml/min 93.2±41.4 100.1±34.6 0.012 
Previous myocardial infarction,% 637 (29.9) 13 (26.0) 0.639 
Previous PCI, % 583 (27.4) 10 (20.0) 0.334 
LVEF,% 54.8±11.6 52.0±10.9 0.01 
Anatomical Characteristics    
Baseline SYNTAX score ±SD 17.1±11.3 18.0±10.2 0.276 
Number of total occlusions/patient±SD 0.33±0.51 0.41±0.56 0.04 
Number of aorto-ostial lesions/patient±SD 0.05±0.23 0.06±0.56 0.566 
Number of lesions with severe tortuosity/patient±SD 0.74±1.07 0.68±1.02 0.425 
Number of lesions with length>20mm/patient±SD 0.51±0.71 0.53±0.62 0.750 
Number of lesions with heavy 
calcification/patient±SD 
0.33±0.77 0.25±0.68 0.158 
Number segments with diffuse disease/patient±SD 0.04±0.20 0.03±0.17 0.531 
Lesions in left main/patient 0.08±0.29 0.06±0.26 0.246 
Lesions in LAD proximal/patient 0.31±0.48 0.33±0.51 0.491 
Lesions in LAD mid/patient 0.56±0.58 0.54±0.60 0.579 
Lesions in LAD apical/patient 0.16±0.39 0.11±0.34 0.08 
Lesions in 1st diagonal/patient 0.24±0.45 0.26±0.46 0.549 
Lesions in 2nd diagonal/patient 0.01±0.12 0.01±0.12 0.875 
Lesions in proximal circumflex/patient 0.18±0.40 0.16±0.37 0.587 
Lesions in distal circumflex/patient 0.32±0.50 0.27±0.47 0.178 
Lesions in intermediate/patient 0.10±0.31 0.07±0.26 0.155 
Lesions in first obtuse marginal/patient 0.13±0.34 0.10±0.32 0.319 
Lesions in second obtuse marginal/patient 0.11±0.33 0.10±0.31 0.559 
Lesions in RCA proximal/patient 0.25±0.44 0.32±0.48 0.026 
Lesions in  RCA mid/patient 0.33±0.48 0.32±0.47 0.734 
Lesions in RCA distal/patient 0.23±0.45 0.26±0.46 0.333 
Lesions in Posterolateral/patient 0.03±0.18 0.02±0.14 0.787 
Lesions in Posterior descending /patient 0.11±0.32 0.12±0.33 0.351 
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Supplemental Figures 
Figure 1. Combined OR using the 3 trials using fixed effects for patients with thrombus 
containing lesions (TCL):
 
 
Figure 2. When the LEADERS Trial was removed from the pooled analysis there was no longer 
heterogeneity: 
 
Figure 3. Also when the RESOLUTE trial was removed from the pooling there was no 
significant heterogeneity: 
 
Figure 4. However, when we pool RESOLUTE and LEADERS and remove from the analysis the 
SYNTAX trial, the heterogeneity became even more evident: 
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Figure 5. Pooled trial results using Bayesian random effects in which TCL did not have impact 
on long-term occurrence of MACE: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Material 
 
Figure 6A. Kaplan-Meier curve comparison for MACE (composite of all-cause death, all myocardial infarctions and all revascularizations) 
according to presence/absence of thrombus containing lesions in patients with stable coronary artery disease  
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Figure 6B. Kaplan-Meier curve comparison for all-cause death according to presence/absence of thrombus containing lesions in patients with 
stable coronary artery disease  
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Figure 6C. Kaplan-Meier curve comparison for myocardial infarction according to presence/absence of thrombus containing lesions in patients 
with stable coronary artery disease  
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Figure 6D. Kaplan-Meier curve comparison for all revascularizations according to presence/absence of thrombus containing lesions in patients 
with stable coronary artery disease  
 
 
 
Supplemental Material 
 
Figure 7A. Adjusted MACE (composite of all-cause death, all myocardial infarctions and all revascularizations) rate comparison according to 
presence/absence of thrombus containing lesions in patients with stable coronary artery disease  
 
 
 
 
 
Supplemental Material 
 
Figure 7B. Adjusted all-cause death rate comparison according to presence/absence of thrombus containing lesions in patients with stable 
coronary artery disease  
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Figure 7C. Adjusted all myocardial infarctions rate comparison according to presence/absence of thrombus containing lesions in patients with 
stable coronary artery disease  
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Figure 7D. Adjusted all revascularizations rate comparison according to presence/absence of thrombus containing lesions in patients with stable 
coronary artery disease  
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